^
Association details:
| Biomarker: | EGFRvIII mutation + EGFR-SEPTIN14 fusion + EGFR amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib
Excerpt:
Here we describe a case of a 63-year-old man...the patient subsequently showed PD, and a new variant, EGFRvIII, appeared in metastasis, which may be involved in erlotinib resistance.
DOI:
10.1634/theoncologist.2019-0405
